Typos… [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2022-03-20 16:08 (323 d 13:06 ago) – Posting: # 22845
Views: 854

Hi Shatha,

this guidance (of 1996!) is hopelessly outdated and notorious for typos… The current one is of 2018.

Why are you interested in reproducing such stuff? If for validation purposes, consider this series of articles instead:
  1. Schütz H, Labes D, Fuglsang A. Reference Datasets for 2-Treatment, 2-Sequence, 2-Period Bioequivalence Studies. AAPS J. 2014; 16(6): 1292–7. doi:10.1208/s12248-014-9661-0. [image] Free Full text.
  2. Fuglsang A, Schütz H, Labes D. Reference Datasets for Bioequivalence Trials in a Two-Group Parallel Design. AAPS J. 2015; 17(2): 400–4. doi:10.1208/s12248-014-9704-6. [image] Free Full text.
  3. Schütz H, Tomashevskiy M, Labes D, Shitova A, González-de la Parra M, Fuglsang A. Reference Data­sets for Studies in a Replicate Design intended for Average Bioequivalence with Expanding Limits. AAPS J. 2020; 22(2): Article 44. doi:10.1208/s12248-020-0427-6.


Edit: Just checked Cmax of TABLE 11-T. You are correct.$$\small{\{L,U\}=100\exp(-0.2708+0.0360\,\mp 1.812\times0.0799)\approx \{68.41\%,91.39\%\}}$$Not rocket science.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,481 posts in 4,710 threads, 1,603 registered users;
16 visitors (1 registered, 15 guests [including 8 identified bots]).
Forum time: 05:14 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5